Recent Updates
Recently added Catalysts

ZIO-101-C

Phase 2

Advanced Cancer | Small Molecules | Oncology |Alaunos Therapeutics, Inc.|Trials Updated: Sep 29, 2026

ZIO-101-C development status

Highest phase Phase 2 (NCT00421213)
Phase scored for TCRTPhase 1
Registered trials 6 across 1 sponsor since Jan 2007

ZIO-101-C target and mechanism

ModalitySmall Molecules

Also known as ZIO-101-C (Darinaparsin), darinaparsin, S-dimethylarsino-glutathione, Zinapar (TM)

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials3
Total Enrollment55

FDA Designations

No designations recorded

ZIO-101-C clinical trials

ZIO-101-C · 3 trials · 3 indications

Phase 1 3
NCT01139346Study of Oral Darinaparsin in Patients With Advanced Solid TumorsAdvanced Solid Tumors
COMPLETED12 Analytics
NCT00592163Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and LymphomasAdvanced Solid Tumors
COMPLETED20 Analytics
NCT00591422Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's LymphomasAdvanced Cancer
COMPLETED23 Analytics
PHASE1COMPLETED
Study of Oral Darinaparsin in Patients With Advanced Solid Tumors
Advanced Solid TumorsUnlock trial analytics
PHASE1COMPLETED
Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas
Advanced Solid TumorsUnlock trial analytics
PHASE1COMPLETED
Phase I Study of Oral Darinaparsin (ZIO-101-C)in Advanced Solid Tumors and Non-Hodgkin's Lymphomas
Advanced CancerUnlock trial analytics

Study Endpoints

Primary Endpoints

Determine Toxicity Profile
One Year

a primary outcome measure is to determine the toxicity profile of oral darinaparsin when given continuously for 21 days followed by a 7 day rest period per cycle

Determine Maximum Tolerated Dose
One Year

a primary outcome measure is to determine the maximum tolerated dose of oral darinaparsin when given continuously for 21 days followed by a 7 day rest period per cycle

Determine the preliminary activity/efficacy
One Year

a primary outcome measure is to determine the preliminary activity/efficacy of oral darinaparsin when given continuously for 21 days followed by a 7 day rest period per cycle

Determine Pharmacokinetic profile
One Year

a primary outcome measure is to determine the pharmacokinetic profile of oral darinaparsin when given continuously for 21 days followed by a 7 day rest period per cycle

toxicities
6 months

Secondary Endpoints

pharmacokinetics
6 months
Unlock Study Endpoints

Study Design & Arms

AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
oral darinaparsinEXPERIMENTALopen label, single arm, dose escalation
Single ArmEXPERIMENTAL -

Interventions

NameTypeDescription
darinaparsinDRUGdose escalating, starting at 200 mg twice per day for 21 days continuous followed by a 7 day rest per cycle.
ZIO-101-C (Darinaparsin)DRUGDose Escalation study, 200 mg - 900 mg, cumulative daily dose split to be taken BID 7 times a week (\>8 hours between doses) for 3 weeks followed by 1 week of rest
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites3

Inclusion Criteria: * Subjects with histological or cytological confirmation of advanced cancer (solid tumor) that is refractory to standard therapies for their condition; * Men and women of ≥18 years of age; * ECOG performance score ≤2 * Eligible subjects with solid tumors MUST have at least one m...

Countries:United StatesCanada
Unlock Eligibility Criteria

Competitive Landscape -Cancer 13 trials (matched to "Advanced Cancer")

Recent Changes (Last 90 Days)

MEDIUMOct 30, 2026NCT00591422TRIAL_REMOVED: changed
MEDIUMOct 30, 2026NCT00592163TRIAL_REMOVED: changed
MEDIUMOct 30, 2026NCT00592163TRIAL_REMOVED: changed
MEDIUMOct 30, 2026NCT00591422TRIAL_REMOVED: changed
MEDIUMOct 30, 2026NCT00592163TRIAL_REMOVED: changed
MEDIUMOct 30, 2026NCT00591422TRIAL_REMOVED: changed

Frequently asked questions about ZIO-101-C

What is ZIO-101-C used for?

ZIO-101-C is an investigational small molecule being studied in advanced cancer, specifically advanced solid tumors and lymphomas. It has been evaluated in Phase 1 clinical trials in adults aged 18 years and older. It is not an approved therapy; the studies were early-stage dose and safety evaluations conducted in Canada and the United States.

Who is developing ZIO-101-C?

ZIO-101-C is being developed by Alaunos Therapeutics, Inc., which trades under the ticker TCRT. The company sponsored the Phase 1 clinical program evaluating oral ZIO-101-C in patients with advanced solid tumors and lymphomas.

What phase is ZIO-101-C in?

ZIO-101-C is in Phase 1 clinical development. Both of its recorded Phase 1 studies in advanced solid tumors and lymphomas have been completed, and no trials are currently active. It is an investigational agent and has not been approved for any indication.

What clinical trials has ZIO-101-C been studied in?

ZIO-101-C has been studied in two completed Phase 1 trials. NCT00592163 evaluated oral ZIO-101-C in advanced solid tumors and lymphomas in Canada with 20 patients. NCT00591422 evaluated oral darinaparsin (ZIO-101-C) in advanced cancer and non-Hodgkin's lymphomas in the United States with 23 patients.

Is ZIO-101-C the same as darinaparsin?

Yes. ZIO-101-C is also known as darinaparsin, and the two names refer to the same investigational small molecule. The Phase 1 trial NCT00591422 is listed under the name oral darinaparsin (ZIO-101-C), confirming that the alternative name identifies the same agent.

How many patients were enrolled in ZIO-101-C trials?

The ZIO-101-C clinical program enrolled a total of 23 patients across its studies. The Phase 1 trial NCT00591422 in advanced cancer and non-Hodgkin's lymphomas accounted for 23 participants, while NCT00592163 in advanced solid tumors and lymphomas enrolled 20 patients. Both studies were uncontrolled and non-randomized.